Cargando…

A systematic review and meta-analysis of BRCA1/2 mutation for predicting the effect of platinum-based chemotherapy in triple-negative breast cancer

INTRODUCTION: Platinum-based chemotherapy (PBC) remains the mainstay of treatments for triple-negative breast cancer (TNBC). TNBC is a heterogeneous group, the issue of whether BRCA1/2 mutation carriers have a particular sensitivity to platinum agents is inconclusive. We conducted a meta-analysis to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jia, Xiaomeng, Wang, Kainan, Xu, Lingzhi, Li, Ning, Zhao, Zuowei, Li, Man
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9471971/ https://www.ncbi.nlm.nih.gov/pubmed/36096071 http://dx.doi.org/10.1016/j.breast.2022.08.012

Ejemplares similares

The effect of neoadjuvant platinum-based chemotherapy in BRCA mutated triple negative breast cancers -systematic review and meta-analysis
por: Caramelo, Olga, et al.
Publicado: (2019)

Combining PARP inhibitors and platinum-based chemotherapy in metastatic triple negative and/or BRCA-associated breast cancer
por: Molto Valiente, Consolacion, et al.
Publicado: (2023)

Platinum-Based Neoadjuvant Chemotherapy for Breast Cancer With BRCA Mutations: A Meta-Analysis
por: Wang, Chang-Jun, et al.
Publicado: (2020)

Efficacy of platinum in advanced triple-negative breast cancer with germline BRCA mutation determined by next generation sequencing
por: Wang, Nan, et al.
Publicado: (2020)

Platinum-based chemotherapy in triple-negative breast cancer: A meta-analysis
por: LIU, MIAO, et al.
Publicado: (2013)

Platinum-based neoadjuvant chemotherapy for triple-negative breast cancer: a systematic review and meta-analysis
por: Li, Zhen-Yu, et al.
Publicado: (2020)

Platinum‐based chemotherapy for early triple‐negative breast cancer
por: Mason, Sofia RE, et al.
Publicado: (2023)

BRCA2 Mutations and Triple-Negative Breast Cancer
por: Meyer, Peter, et al.
Publicado: (2012)

Chemotherapy of metastatic triple negative breast cancer: Experience of using platinum-based chemotherapy
por: Zhang, Jian, et al.
Publicado: (2015)

Cisplatin +/− rucaparib after preoperative chemotherapy in patients with triple-negative or BRCA mutated breast cancer
por: Kalra, Maitri, et al.
Publicado: (2021)

Homologous Recombination Deficiency (HRD) and BRCA 1/2 Gene Mutation for Predicting the Effect of Platinum-Based Neoadjuvant Chemotherapy of Early-Stage Triple-Negative Breast Cancer (TNBC): A Systematic Review and Meta-Analysis
por: Chai, Yue, et al.
Publicado: (2022)

BRCA1 mutation in the Triple- Negative Breast Cancer Group
por: Maksimenko, Jelena, et al.
Publicado: (2012)

Effects of BRCA Germline Mutations on Triple-Negative Breast Cancer Prognosis
por: Pogoda, Katarzyna, et al.
Publicado: (2020)

A meta-analysis of the effect and safety of platinum-based neoadjuvant chemotherapy in treatment of resectable triple-negative breast cancer
por: Feng, Wuna, et al.
Publicado: (2021)

Comprehensive molecular comparison of BRCA1 hypermethylated and BRCA1 mutated triple negative breast cancers
por: Glodzik, Dominik, et al.
Publicado: (2020)

Prognostic role of BRCA1 mutation in patients with triple-negative breast cancer
por: MAKSIMENKO, JELENA, et al.
Publicado: (2014)

Association between homologous recombination deficiency and outcomes with platinum and platinum-free chemotherapy in patients with triple-negative breast cancer
por: Chen, Yimeng, et al.
Publicado: (2023)

Efficacy of platinum-based and non-platinum-based drugs on triple-negative breast cancer: meta-analysis
por: Lin, Canling, et al.
Publicado: (2022)

Association Between BRCA Status and Triple-Negative Breast Cancer: A Meta-Analysis
por: Chen, Haixia, et al.
Publicado: (2018)

The prevalence of BRCA1 mutations among young women with triple-negative breast cancer
por: Young, SR, et al.
Publicado: (2009)

Platinum-Based Chemotherapy and Immunotherapy in Early Triple-Negative Breast Cancer: A Meta-Analysis and Indirect Treatment Comparison
por: He, Qin, et al.
Publicado: (2021)

Influence of BRCA1 Germline Mutations in the Somatic Mutational Burden of Triple-Negative Breast Cancer
por: Ferreira, Elisa Napolitano, et al.
Publicado: (2019)

Targeting glutamine metabolism enhances responses to platinum-based chemotherapy in triple-negative breast cancers (TNBC)
por: Hong, Jiaxin, et al.
Publicado: (2022)

Platinum is essential in neoadjuvant treatment of triple-negative breast cancer: a network meta-analysis
por: Li, Junjie, et al.
Publicado: (2022)

Triple-negative breast cancer frequency and type of BRCA mutation: Clues from Sardinia
por: PALOMBA, GRAZIA, et al.
Publicado: (2014)

Triple-negative Breast Cancer Arising in a Fibroadenoma in BRCA 1 Mutated Patient
por: Brunetti, Nicole, et al.
Publicado: (2022)

Efficacy of different neoadjuvant treatment regimens in BRCA-mutated triple negative breast cancer: a systematic review and meta-analysis
por: Caramelo, Olga, et al.
Publicado: (2022)

53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers
por: Bouwman, Peter, et al.
Publicado: (2010)

Matched cohort study of germline BRCA mutation carriers with triple negative breast cancer in brightness
por: Metzger-Filho, Otto, et al.
Publicado: (2021)

LncRNA AWPPH promotes the growth of triple-negative breast cancer by up-regulating frizzled homolog 7 (FZD7)
por: Wang, Kainan, et al.
Publicado: (2018)

BRCA-mutated gastric adenocarcinomas are associated with chromosomal instability and responsiveness to platinum-based chemotherapy
por: Oh, Ji Hyun, et al.
Publicado: (2023)

ERCC1 Expression in Metastatic Triple Negative Breast Cancer Patients Treated with Platinum-Based Chemotherapy
por: Baiomy, Mohamed Ali EL, et al.
Publicado: (2017)

Efficacy of PARP Inhibitor, Platinum, and Immunotherapy in BRCA-Mutated HER2-Negative Breast Cancer Patients: A Systematic Review and Network Meta-Analysis
por: Sun, Wanyi, et al.
Publicado: (2023)

A Single Institution Experience of Incorporation of Cisplatin into Adjuvant Chemotherapy for Patients With Triple-Negative Breast Cancer of Unknown BRCA Mutation Status
por: Su, Ying-Wen, et al.
Publicado: (2018)

BRCA Mutation Status in Triple-Negative Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: A Pivotal Role for Treatment Decision-Making
por: Pavese, Francesco, et al.
Publicado: (2022)

Bilateral Triple Negative Invasive Ductal Breast Carcinoma in a BRCA1 Mutation Carrier with Discrepant Pathologic Response to Neoadjuvant Chemotherapy
Publicado: (2020)

Triple negative breast cancer and platinum-based systemic treatment: a meta-analysis and systematic review
por: Pandy, Jessa Gilda P., et al.
Publicado: (2019)

Androgen Receptor, EGFR, and BRCA1 as Biomarkers in Triple-Negative Breast Cancer: A Meta-Analysis
por: Zhang, Li, et al.
Publicado: (2015)

Genomic and epigenomic BRCA alterations predict adaptive resistance and response to platinum-based therapy in patients with triple negative breast and ovarian carcinomas
por: Menghi, Francesca, et al.
Publicado: (2022)

Triple-negative breast cancer: BRCAness and concordance of clinical features with BRCA1-mutation carriers
por: Lips, E H, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_rfh25s5n0agjmouhu657b4almg